SCHEMBL5271422

SCHEMBL5271422

CCOC(=O)c1ccc(-c2n[nH]c(C)c2I)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.64
▸ CA12 O43570 1/20 0.47
▸ CA1 P00915 1/20 0.47
▸ CA2 P00918 1/20 0.47
▸ ESR1 P03372 1/20 0.47
▸ CA7 P43166 1/20 0.47
▸ CA9 Q16790 1/20 0.47
▸ ESR2 Q92731 1/20 0.47
▸ CA14 Q9ULX7 1/20 0.47
▸ RARA P10276 1/20 0.47
▸ RARB P10826 1/20 0.47
▸ RARG P13631 1/20 0.47
▸ TSHR P16473 4/20 0.47
▸ TP53 P04637 4/20 0.47
▸ USP2 O75604 3/20 0.47
▸ ALDH1A1 P00352 3/20 0.47
▸ NPSR1 Q6W5P4 2/20 0.47
▸ MAPK1 P28482 2/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5272446 0.84 KDM4E (0.50) KDM4ETP53ALDH1A1HPGDSMAPT
SCHEMBL4488472 0.77 KDM4E (0.74) KDM4ERARARARBRARGALDH1A1
SCHEMBL5173650 0.77 PDE4D (0.55) KDM4ERARARARBRARGTSHR
SCHEMBL25171648 0.76 DUSP3 (0.56) KDM4ECA12CA9ALDH1A1MEN1
SCHEMBL19805499 0.76 KDM4E (0.49) KDM4EALDH1A1NPSR1MAPK1ALOX5
SCHEMBL1965326 0.75 CA1 (0.73) KDM4ECA12CA1CA2ESR1
SCHEMBL16351874 0.75 CA1 (0.73) KDM4ECA12CA1CA2ESR1
SCHEMBL5267093 0.74 ALPL (0.59) KDM4ECA12CA1CA2ESR1
SCHEMBL4349663 0.74 KDM4E (0.59) KDM4ECA12CA1CA2ESR1
SCHEMBL10607787 0.74 CA1 (0.61) KDM4ECA12CA1CA2ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1456180-B1 3-(2,4)DIHYDROXYPHENYL-4-PHENYLPYRAZOLES AND THEIR MEDICAL USE VERNALIS CAMBRIDGE LTD (GB) 2007-10-03 — — EP disclosed
US-7247734-B2 3,4-diarylpyrazoles and their use in the therapy of cancer VERNALIS (CAMBRIDGE) LIMITED (GB) 2007-07-24 — — US disclosed
US-20050222230-A1 3,4-diarylpyrazoles and their use in the therapy of cancer VERNALIS (CAMBRIDGE) LIMITED (GB) 2005-10-06 — — US disclosed
EP-1456180-A1 3,4-DIARYLPYRAZOLES AND THEIR USE IN THE THERAPY OF CANCER Vernalis (Oxford) Ltd (GB) 2004-09-15 — — EP disclosed
WO-2003055860-A1 3,4-DIARYLPYRAZOLES AND THEIR USE IN THE THERAPY OF CANCER VERNALIS (CAMBRIDGE) LIMITED (GB) 2003-07-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222230-A1 3,4-diarylpyrazoles and their use in the therapy of cancer HSP90AB1, HSP90AA1, HSP90AB2P KDM4E 1999/4885CA12 4387/4885CA1 3753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback